Bio/Pharma News

Mar 22, 2018
By Pharmaceutical Technology Editors
Helsinn will acquire the global rights to Valchlor/Ledaga (mechlorethamine/chlormethine), a topical skin-cancer drug, from Actelion Pharmaceuticals.
Mar 21, 2018
By Pharmaceutical Technology Editors
AbbVie and the International Myeloma Foundation will partner to study the role of a genetic mutation in outcomes of patients with multiple myeloma.
Mar 19, 2018
By Pharmaceutical Technology Editors
The companies intend to jointly develop and commercialize Lenvima (lenvatinib mesylate) as a monotherapy and an in-combination therapy for treating multiple cancer types.
Mar 19, 2018
By Pharmaceutical Technology Editors
Biogen will acquire an AMPA receptor potentiator for cognitive impairment associated with schizophrenia in a deal worth approximately $590 million.
Mar 13, 2018
By Pharmaceutical Technology Editors
The $11.6-billion acquisition strengthens Sanofi's position in hematology and specialty medicines.
Mar 09, 2018
Pharmaceutical Technology
By Pharmaceutical Technology Editors
The European Medicines Agency has called for the immediate suspension and recall of AbbVie and Biogen's multiple sclerosis drug Zinbryta (daclizumab beta).
Mar 08, 2018
By Pharmaceutical Technology Editors
Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.
Mar 06, 2018
By Pharmaceutical Technology Editors
The companies will join forces to develop next-generation ex vivo cell therapies in oncology.
Mar 06, 2018
By Pharmaceutical Technology Editors
The companies will work together to develop prescription digital therapeutics for patients with schizophrenia and multiple sclerosis.
Mar 06, 2018
By Pharmaceutical Technology Editors
The pharma major will spin out six molecules in early stage inflammation and autoimmune programs into a new company called Viela Bio.
native1_300x100
lorem ipsum